Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 15, 21 | -0.75
Increased by
+16.67%
|
-0.75 |
Aug 16, 21 | -0.90
Increased by
+45.45%
|
-0.90 |
May 17, 21 | -0.90
Increased by
+25.00%
|
-0.90 |
Mar 31, 21 | -0.90
Increased by
+81.82%
|
-0.90 |
Nov 4, 20 | -0.90
Increased by
+57.14%
|
-1.50
Increased by
+40.00%
|
Aug 14, 20 | -1.65
Increased by
+74.42%
|
-1.50
Decreased by
-10.00%
|
May 11, 20 | -1.20
Increased by
+90.24%
|
-2.55
Increased by
+52.94%
|
Mar 30, 20 | -4.95
Increased by
+10.81%
|
-4.20
Decreased by
-17.86%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-662.00 K
Increased by
+76.51%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-604.00 K
Increased by
+36.35%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-2.86 M
Decreased by
-186.67%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-3.73 M
Decreased by
-72.43 M%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-2.82 M
Decreased by
-174.12%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-949.00 K
Increased by
+49.74%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-998.00 K
Increased by
+19.65%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-5.15
Increased by
+100.00%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.